Everyday Health on MSN
Is your atopic dermatitis well-controlled? 3 red flags you should watch for
Learn the red flags that indicate the eczema treatment plan you’re on isn’t working.
Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...
The percentage of patients achieving total clearance of eczema lesions in a Phase 2b trial increased with prolonged rezpeg treatment.
Everyday Health on MSN
Special summer care for eczema: Tips from our dermatology experts
Learn how to manage eczema during summer with advice from dermatologists. Get tips on moisturizing, using sunscreen, and wearing protective clothing to help itchy skin.
Although eczema affects many adults, it is more common in children. Eczema is a general term to describe a number of inflammatory skin conditions. Aside from atopic dermatitis (the most prevalent), ...
Nektar Therapeutics (NKTR) stock jumps on positive mid-stage trial data for its experimental drug targeting atopic dermatitis. Read more here.
Atopic dermatitis, the most common form of eczema, can lead to a range of complications that go beyond skin issues to include those involving eye health and mental health. People with atopic ...
Treating our son, Kyan, for atopic dermatitis (eczema) has been a long haul. He was about 6 weeks old when we first noticed that he was breaking out in rashes. That was in May or June of 2013. We just ...
Topical corticosteroids are recommended as first-line treatment for all levels of atopic dermatitis, as well as for maintenance therapy.
Eczema is a group of skin conditions that makes your skin irritated, inflamed, and itchy. Your doctor might also call it dermatitis. It weakens your skin’s barrier function, which protects you from ...
Eczema or atopic dermatitis is a condition which makes you skin seem red and itchy. Eczema is common in children but it can occur at any age. It is characterised by patches of skin becoming inflamed, ...
Evommune has aced its first major test as a public company, reporting phase 2a eczema data that caused its share price to jump 75% in premarket trading. The biotech, which went public late last year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results